Racura is pursuing one of cancer’s most elusive targets, pairing a distinctive MYC-inhibition approach with a data-first path ...
Zymeworks entered into a global licensing and collaboration agreement with Roche for ZW209, a trispecific T-cell engager ...
Gilead Sciences has agreed to acquire an oral IL-23R inhibitor program, led by HCXT-2001, from privately held PepStar ...
BioXconomy highlights leading Black innovators and leaders in the biotechnology industry.
Earlier this week, Eli Lilly announced it broke ground on a large site in Houston, Texas. The location will be one of ten US ...
METiS TechBio has teamed up with Lilly in a deal worth $1.1bn, pairing AI-driven lipid design with pharma expertise to ...
Molecular testing firm Qiagen has agreed to a $52.22-per-share all-cash acquisition by EQT Private Equity.
Germany’s Merck has agreed to acquire London-based Silence Therapeutics in an all-cash deal, adding a late-stage rare blood ...
IQVIA and Veeva extend their partnership, expanding sponsor access to Veeva's clinical trial and data management technology.
Estuary Biotherapeutics launches with $103 million to take gene therapies for kidney disease into the clinic. The financing ...
The clinical-stage biotech has closed an oversubscribed Series D financing round in a bid to meeting its mission to stop ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results